Medical complications of lung transplantation

European Respiratory Journal

Volumn 23, Issue 2, 2004, Pages 334-342

  Kotloff, R M ^a   Ahya, V N ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Immunosuppressive agents; Lung transplantation; Lymphoproliferative disorders; Pneumonia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BENZOIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCITONIN; CALCIUM; CORTICOSTEROID; CYCLOSPORIN A; FOSCARNET; GANCICLOVIR; GLUCOCORTICOID; ITRACONAZOLE; PAMIDRONIC ACID; PARATHYROID HORMONE; PHENYLACETIC ACID; RAPAMYCIN; RITUXIMAB; TACROLIMUS; VALGANCICLOVIR; VITAMIN D; VORICONAZOLE;

ASPERGILLOSIS; BACTERIAL INFECTION; CANCER RISK; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERAMMONEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFECTIOUS COMPLICATION; LEUKOENCEPHALOPATHY; LIFE EXPECTANCY; LUNG CANCER; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; OUTCOMES RESEARCH; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECIPIENT; RETROSPECTIVE STUDY; REVIEW; STROKE; SURVIVAL RATE;

CAUSE OF DEATH; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; RISK; SURVIVAL ANALYSIS;

EID: 0242641800     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00043403     Document Type: Review

References (96)

1. Maurer JR, Tullis E, Grossman RF, Vellend H, Winton TL, Patterson GA. Infectious complications following isolated lung transplantation. Chest 1992; 101: 1056-1059.
2. Kramer MR, Marshall SE, Starnes VA, Garnberg P, Amitai Z, Theodore J. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 1993; 153: 2010-2016.
3. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transplant Infect Dis 2001; 3: 128-137.
4. Weill D, Dey GC, Hicks RA, et al. A positive donor gram stain does not predict outcome following lung transplantation. J Heart Lung Transplant 2002; 21: 555-558.
5. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994; 149: 1601-1607.
6. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155: 1699-1704.
7. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164: 2102-2106.
8. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163: 43-48.
9. Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146: 1419-1425.
10. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
11. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am Rev Respir Dis 1993; 147: 1017-1023.
12. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119-1126.
13. Rubin RH. Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000; 19: 731-735.
14. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21: 1274-1282.
15. Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999; 68: 1272-1279.
16. Zamora MR. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant 2002; 21: 841-849.
17. Hertz MI, Jordan C, Savik SK, et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998; 17: 913-920.
18. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996; 15: 881-887.
19. Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150: 146-152.
20. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP 3rd. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001; 119: 169-175.
21. Paradowski LJ. Saprophytic fungal infections and lung transplantation-Revisited. J Heart Lung Transplant 1997; 16: 524-531.
22. Cahill B, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160-1164.
23. Kessler R, Massard G, Warter A, Wihlm JM, Weitzenblum E. Bronchial-pulmonary artery fistula after unilateral lung transplantation: a case report. J Heart Lung Transplant 1997; 16: 674-677.
24. Birsan T, Taghavi S, Klepetko W. Treatment of aspergillus-related ulcerative tracheobronchitis in lung transplant recipients. J Heart Lung Transplant 1998; 17: 437-438.
25. Nunley DR, Gal AA, Vega JD, Perlino C, Smith P, Lawrence EC. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest 2002; 122: 1185-1191.
26. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001; 3: 161-167.
27. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78: 123-138.
28. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
29. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627-628.
30. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996; 154: 1712-1717.
31. Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest 1999; 116: 1273-1277.
32. Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001; 20: 1054-1063.
33. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728.
34. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877-887.
35. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165-1171.
36. Tsai DE, Nearey M, Hardy CL, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant 2002; 2: 946-954.
37. Green M, Webber SA. EBV viral load monitoring: unanswered questions. Am J Transplant 2002; 2: 894-895.
38. Reynaud-Gaubert M, Stoppa AM, Gaubert J, Thomas P, Fuentes P. Anti-CD20 monoclonal antibody therapy in Epstein-Barr Virus-associated B cell lymphoma following lung transplantation. J Heart Lung Transplant 2000; 19: 492-495.
39. Verschuuren EA, Stevens SJ, van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73: 100-104.
40. Niedermeyer J, Hoffmeyer F, Hertenstein B, Hoeper MM, Fabel H. Treatment of lymphoproliferative disease with rituximab. Lancet 2000; 355: 499.
41. Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21: 547-554.
42. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999; 96: 10391-10396.
43. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088.
44. Arcasoy SM, Hersh C, Christie JD, et al. Bronchogenic carcinoma complicating lung transplantation. J Heart Lung Transplant 2001; 20: 1044-1053.
45. Collins J, Kazerooni EA, Lacomis J, et al. Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings. Radiology 2002; 224: 131-138.
46. Penn I. Posttransplant malignancies. Transplant Proc 1999; 31: 1260-1262.
47. Garver RI Jr, Zorn GL, Wu X, McGiffin DC, Young KR Jr, Pinkard NB. Recurrence of bronchioloalveolar carcinoma in transplanted lungs. N Engl J Med 1999; 340: 1071-1074.
48. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
49. Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. Chest 2000; 117: 476-481.
50. Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest 1996; 109: 1176-1183.
51. Tschopp O, Boehler A, Speich R, et al. Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant 2002; 2: 167-172.
52. Donovan DS Jr, Papadopoulos A, Staron RB, et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 1998; 157: 1892-1899.
53. Biskobing DM. COPD and osteoporosis. Chest 2002; 121: 609-620.
54. Romero DF, Buchinsky FJ, Rucinski B, et al. Rapamycin: a bone sparing immunosuppressant? J Bone Miner Res 1995; 10: 760-768.
55. Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994; 57: 1231-1237.
56. Shui C, Riggs BL, Khosla S. The immunosuppressant rapamycin, alone or with transforming growth factor-b, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand. Calcif Tissue Int 2002; 71: 437-446.
57. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496-1503.
58. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173-1177.
59. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-387.
60. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292-299.
61. Aris RM, Lester GE, Renner JB, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 2000; 162: 941-946.
62. Cahill BC, O'Rourke MK, Parker S, Stringham JC, Karwande SV, Knecht TP. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation 2001; 72: 1251-1255.
63. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
64. Watts NB, Harris ST, Genant HK. Treatment of painful osteoporotic vertebral fractures with percutaneous vertebroplasty or kyphoplasty. Osteoporos Int 2001; 12: 429-437.
65. Lubetkin EI, Lipson DA, Palevsky HI, et al. GI complications after orthotopic lung transplantation. Am J Gastroenterol 1996; 91: 2382-2390.
66. Berkowitz N, Schulman LL, McGregor C, Markowitz D. Gastroparesis after lung transplantation. Potential role in postoperative respiratory complications. Chest 1995; 108: 1602-1607.
67. Palmer SM, Miralles AP, Howell DN, Brazer SR, Tapson VF, Davis RD. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest 2000; 118: 1214-1217.
68. Lau CL, Palmer SM, Howell DN, et al. Laparoscopic antireflux surgery in the lung transplant population. Surg Endosc 2002; 16: 1674-1678.
69. Goldstein LS, Haug MT 3rd, Perl J 2nd, et al. Central nervous system complications after lung transplantation. J Heart Lung Transplant 1998; 17: 185-191.
70. Thyagarajan GK, Cobanoglu A, Johnston W. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. Ann Thorac Surg 1997; 64: 1461-1464.
71. Nakamura M, Fuchinoue S, Sato S, et al. Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation. Transplant Proc 1998; 30: 1477-1478.
72. Lanzino G, Cloft H, Hemstreet MK, West K, Alston S, Ishitani M. Reversible posterior leukoencephalopathy following organ transplantation. Description of two cases. Clin Neurol Neurosurg 1997; 99: 222-226.
73. Drachman BM, DeNofrio D, Acker MA, Galetta S, Loh E. Cortical blindness secondary to cyclosporine after orthotopic heart transplantation: a case report and review of the literature. J Heart Lung Transplant 1996; 15: 1158-1164.
74. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 1987; 317: 861-866.
75. Nussbaum ES, Maxwell RE, Bitterman PB, Hertz MI, Bula W, Latchaw RE. Cyclosporine A toxicity presenting with acute cerebellar edema and brainstem compression. Case report. J Neurosurg 1995; 82: 1068-1070.
76. Stang MR, Hinderliter AL, Gott KK, Paradowski LJ, Aris RM. Atrial anastomotic thrombus causes neurologic deficits in a lung transplant recipient. Transplantation 1996; 62: 693-695.
77. Lichtenstein GR, Yang YX, Nunes FA, et al. Fatal hyperammonemia after orthotopic lung transplantation. Ann Intern Med 2000; 132: 283-287.
78. Tuchman M, Lichtenstein GR, Rajagopal BS, et al. Hepatic glutamine synthetase deficiency in fatal hyperammonemia after lung transplantation. Ann Intern Med 1997; 127: 446-449.
79. Berry GT, Bridges ND, Nathanson KL, et al. Successful use of alternate waste nitrogen agents and hemodialysis in a patient with hyperammonemic coma after heart-lung transplantation. Arch Neurol 1999; 56: 481-484.
80. Ishani A, Erturk S, Hertz MI, Matas AJ, Savik K, Rosenberg ME. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61: 2228-2234.
81. Pattison JM, Petersen J, Kuo P, Valantine V, Robbins RC, Theodore J. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995; 26: 643-648.
82. Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation 2000; 69: S5-S10.
83. Camara NO, Matos AC, Rodrigues DA, Pereira AB, Pacheco-Silva A. Early detection of heart transplant patients with increased risk of ciclosporin nephrotoxicity. Lancet 2001; 357: 856-857.
84. Ladefoged SD, Andersen CB. Calcium channel blockers in kidney transplantation. Clin Transplant 1994; 8: 128-133.
85. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732-736.
86. Israni A, Brozena S, Pankewycz O, Grossman R, Bloom R. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kidney Dis 2002; 39: E16.
87. Hernandez-Herrera G, Castillo DD, Perez R, Lopez-Rubio F, Aljama P. Tacrolimus rescue therapy for cyclosporine-induced nephrotoxicity. Transpl Int 1998; 11: Suppl. 1, S104-S106.
88. Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998; 30: 1240-1242.
89. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540-546.
90. Young BA, Marsh CL, Alpers CE, Davis CL. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 1996; 28: 561-571.
91. Galli FC, Damon LE, Tomlanovich SJ, Keith F, Chatterjee K, DeMarco T. Cyclosporine-induced hemolytic uremic syndrome in a heart transplant recipient. J Heart Lung Transplant 1993; 12: 440-444.
92. Myers JN, Shabshab SF, Burton NA, Nathan SD. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. J Heart Lung Transplant 1999; 18: 1024-1026.
93. Walder B, Ricou B, Suter PM. Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation. J Heart Lung Transplant 1998; 17: 1004-1006.
94. Neild GH, Ivory K, Williams DG. Glomerular thrombosis and cortical infarction in cyclosporin-treated rabbits with acute serum sickness. Br J Exp Pathol 1984; 65: 133-144.
95. Butkus DE, Herrera GA, Raju SS. Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation. Transplantation 1992; 54: 159-162.
96. Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int 1996; 9: 68-75.